PT931092E - Variantes de factor de crescimento de celulas endoteliais vasculares que possuem propriedades antagonistas - Google Patents

Variantes de factor de crescimento de celulas endoteliais vasculares que possuem propriedades antagonistas

Info

Publication number
PT931092E
PT931092E PT97946328T PT97946328T PT931092E PT 931092 E PT931092 E PT 931092E PT 97946328 T PT97946328 T PT 97946328T PT 97946328 T PT97946328 T PT 97946328T PT 931092 E PT931092 E PT 931092E
Authority
PT
Portugal
Prior art keywords
vegf
variant
growth factor
vascular endothelial
present
Prior art date
Application number
PT97946328T
Other languages
English (en)
Inventor
Bruce A Keyt
Napoleone Ferrara
Francis Hung Nguyen
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PT931092E publication Critical patent/PT931092E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT97946328T 1996-10-17 1997-10-10 Variantes de factor de crescimento de celulas endoteliais vasculares que possuem propriedades antagonistas PT931092E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/734,443 US6750044B1 (en) 1996-10-17 1996-10-17 Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids

Publications (1)

Publication Number Publication Date
PT931092E true PT931092E (pt) 2004-05-31

Family

ID=24951725

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97946328T PT931092E (pt) 1996-10-17 1997-10-10 Variantes de factor de crescimento de celulas endoteliais vasculares que possuem propriedades antagonistas

Country Status (11)

Country Link
US (3) US6750044B1 (pt)
EP (1) EP0931092B1 (pt)
JP (2) JP2000507456A (pt)
AT (1) ATE257485T1 (pt)
AU (1) AU718327B2 (pt)
CA (1) CA2267661C (pt)
DE (1) DE69727149T2 (pt)
DK (1) DK0931092T3 (pt)
ES (1) ES2214640T3 (pt)
PT (1) PT931092E (pt)
WO (1) WO1998016551A2 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
DK1140173T4 (da) 1998-12-22 2013-06-10 Genentech Inc Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf
US7090834B1 (en) 1999-04-16 2006-08-15 Genentech, Inc. Vascular endothelial cell growth factor variants and uses thereof
ES2265931T3 (es) * 1999-04-16 2007-03-01 Genentech, Inc. Variantes del factor de crecimiento celular endotelial vascular (vegf) y sus usos.
JP2003507006A (ja) 1999-05-20 2003-02-25 サイオス，インコーポレーテッド 血管内皮増殖因子改変体
AU6600400A (en) * 1999-08-13 2001-03-13 Crucell Holland B.V. Methods and means for inhibiting angiogenesis
AU782158B2 (en) * 1999-11-02 2005-07-07 Genentech Inc. Modulation of eNOS activity and therapeutic uses thereof
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
US7355019B2 (en) * 2000-06-06 2008-04-08 Sibtech, Inc. Cysteine-containing peptide tag for site-specific conjugation of proteins
AU2002338313A1 (en) * 2001-04-06 2002-10-21 Maxygen Holdings Ltd. Single chain dimeric polypeptides derived from the vegf family
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
DE60237282D1 (de) * 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
ATE462006T1 (de) * 2001-08-01 2010-04-15 Univ Bristol Isoform des vegfs
ES2263984T3 (es) * 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
DK2269656T3 (da) 2002-07-15 2014-11-03 Univ Texas Udvalgte antistoffer, som binder til aminophospholipider og deres anvendelse i behandling, så som cancer
EP1578801A2 (en) * 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
WO2008109433A2 (en) 2007-03-02 2008-09-12 The Cleveland Clinic Foundation Anti-angiogenic peptides
KR101444717B1 (ko) 2003-07-02 2014-09-26 노보 노르디스크 에이/에스 Ｎｋ 세포 활성을 조절하기 위한 조성물 및 방법
US20090191213A9 (en) 2003-07-02 2009-07-30 Novo Nordisk A/S Compositions and methods for regulating NK cell activity
DK2287195T3 (da) 2004-07-01 2019-08-19 Innate Pharma Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi
ATE548389T1 (de) 2004-08-03 2012-03-15 Innate Pharma Therapeutische und diagnostische verfahren und zusammensetzungen zum targeting von 4ig-b7-h3 und dem entsprechenden nk-zellen-rezeptor
WO2006070286A2 (en) 2004-12-28 2006-07-06 Innate Pharma S.A. Monoclonal antibodies against nkg2a
PT1836225E (pt) 2005-01-06 2012-01-10 Novo Nordisk As Agentes de ligação a kir e métodos de utilização dos mesmos
CN101277704A (zh) * 2005-04-12 2008-10-01 因特拉迪格姆公司 用于治疗癌症及其它新血管生成疾病的RNAi治疗剂的组合物和方法
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
TW200732347A (en) * 2005-10-06 2007-09-01 Trophogen Inc VEGF analogs and methods of use
WO2007063308A2 (en) * 2005-12-01 2007-06-07 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
BRPI0621124A2 (pt) 2005-12-22 2011-11-29 Genentech Inc métodos para recuperação de uma proteìna de ligação à heparina
SG162834A1 (en) 2006-07-14 2010-07-29 Genentech Inc Refolding of recombinant proteins
EP2068877A4 (en) 2006-07-19 2011-09-21 Cleveland Clinic Foundation COMPOUNDS AND METHODS FOR MODULATING ANGIOGENESIS
CN101523220B (zh) * 2006-10-04 2016-09-21 健泰科生物技术公司 针对vegf的elisa
EP2083830A1 (en) 2006-11-17 2009-08-05 Innate Pharma Improved methods of using phosphoantigen for the treatment of cancer
WO2008149147A2 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
JP5809415B2 (ja) 2007-11-09 2015-11-10 ペレグリン ファーマシューティカルズ，インコーポレーテッド 抗ｖｅｇｆ抗体の組成物および方法
CA2737146A1 (en) 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Clip inhibitors and methods of modulating immune function
US10457713B2 (en) 2012-07-30 2019-10-29 Trophogen, Inc. Glycoprotein hormone long-acting superagonists
RS58881B1 (sr) 2012-07-30 2019-08-30 Trophogen Inc Dugodelujući superagonisti glikoproteinskih hormona
KR20160101906A (ko) 2013-11-05 2016-08-26 트로포젠 인코포레이티드 당단백질 호르몬의 장시간-작용하는 초작용제
EP3216458A1 (en) 2016-03-07 2017-09-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Modified vascular endothelial growth factor a (vegf-a) and its medical use
EP3576726A1 (en) 2017-02-06 2019-12-11 Massachusetts Institute Of Technology Methods and products related to glutaminase inhibitors
JP2021522308A (ja) 2018-05-04 2021-08-30 トゥリーズ 上皮細胞及び骨髄細胞の両方を活性化するｔｌｒ３リガンド
CN114606240B (zh) * 2022-03-15 2023-05-09 暨南大学 特异性识别血管内皮生长因子的核酸适配体及用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456550A (en) 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US5008196A (en) 1987-08-21 1991-04-16 Monsanto Company Stimulation of endothelial cell growth
US5036003A (en) 1987-08-21 1991-07-30 Monsanto Company Antibodies to VPF
US5008195A (en) * 1988-08-05 1991-04-16 Uop Some novel producers of cyclodextrin glycosyltransferases
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
AU648630B2 (en) * 1990-12-21 1994-04-28 Creative Biomolecules, Inc. Biosynthetic PDGF antagonists
EP0536350B1 (en) 1991-02-22 2002-08-07 American Cyanamid Company Identification of a novel human receptor tyrosine kinase gene
US5185438A (en) 1991-04-02 1993-02-09 The Trustees Of Princeton University Nucleic acids encoding hencatoporetic stem cell receptor flk-2
CN1701814A (zh) 1992-11-13 2005-11-30 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k－1
JP3734262B2 (ja) 1993-03-25 2006-01-11 メルク エンド カンパニー インコーポレーテッド 血管内皮細胞増殖因子阻害剤
GB9410534D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor

Also Published As

Publication number Publication date
ATE257485T1 (de) 2004-01-15
JP2004339233A (ja) 2004-12-02
US20070238659A1 (en) 2007-10-11
JP2000507456A (ja) 2000-06-20
CA2267661A1 (en) 1998-04-23
WO1998016551A2 (en) 1998-04-23
CA2267661C (en) 2005-08-23
EP0931092A2 (en) 1999-07-28
DE69727149D1 (de) 2004-02-12
AU5152398A (en) 1998-05-11
DE69727149T2 (de) 2004-10-28
WO1998016551A3 (en) 1998-05-28
ES2214640T3 (es) 2004-09-16
US20040152636A1 (en) 2004-08-05
US6750044B1 (en) 2004-06-15
EP0931092B1 (en) 2004-01-07
DK0931092T3 (da) 2004-05-17
AU718327B2 (en) 2000-04-13

Similar Documents

Publication Publication Date Title
PT931092E (pt) Variantes de factor de crescimento de celulas endoteliais vasculares que possuem propriedades antagonistas
Oldberg et al. Identification of a bone sialoprotein receptor in osteosarcoma cells.
von der Mark et al. Immunochemistry, genuine size and tissue localization of collagen VI
Yu et al. Importance of FSH-releasing protein and inhibin in erythrodifferentiation
CLAPP et al. Biological and immunological characterization of cleaved and 16K forms of rat prolactin
NZ236511A (en) Polypeptides containing sequences from residues 61 to 82 or 104 to 129 of human il-4 or subsequences thereof; antibodies and pharmaceutical compositions
US20110076234A1 (en) Peptides comprising an isodgr motif
ZA943464B (en) Vascular endothelial growth factor 2
EP0325224A3 (en) Methods of producing secreted receptor analogs and biologically active peptide dimers.
NO312965B1 (no) Blodplate-aggregasjonsinhibitorer
DE60125381D1 (de) Zusammensetzungen und verfahren mit analogen von g-csf
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
KR890009978A (ko) 고정화된 인터루킨(interleukin)2 및 카복실-말단에 연장 펩티드를 함유한 인터루킨2
IL100343A0 (en) G protein coupled glutamate receptors
DE68918867D1 (de) Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
NL8921262A (nl) Neutrofiel-activerend peptide-2, werkwijzen voor het bereiden van deze factor en preparaten die dit peptide bevatten.
WO2002012345A3 (en) Soluble zcytor 11 cytokine receptors
Palaszynski Synthetic C-terminal peptide of IL-1 functions as a binding domain as well as an antagonist for the IL-1 receptor
AU1208497A (en) Ligand polypeptides for the g-protein-coupled receptor protein, their production and use
Hess et al. The agonist selectivity of a mouse B1 bradykinin receptor differs from human and rabbit B1 receptors
Lenert et al. Human CD4 binds immunoglobulins
Bab et al. Isolation of mitogenically active C‐terminal truncated pentapeptide of osteogenic growth peptide from human plasma and culture medium of murine osteoblastic cells
HUP9900979A2 (hu) Endoteliális sejtek proliferációját gátló inhibitor és eljárás alkalmazására
ATE196775T1 (de) Gereinigte flt3 liganden von saeugentieren, agonisten und antagonisten davon
Ivanovski et al. Periodontal‐derived cells attach to cementum attachment protein via α5β1 integrin